Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies
Conditions
- CD5+ Relapsed/Refractory Hematopoietic Malignancies
- Chronic Lymphocytic Leukemia (CLL)
- Mantle Cell Lymphoma (MCL)
- Diffuse Large B-cell Lymphoma (DLBCL)
- Follicular Lymphoma (FL)
- Peripheral T-cell Lymphomas (PTCL)
Interventions
- BIOLOGICAL: CT125A cells
- DRUG: Cyclophosphamide, fludarabine
Sponsor
Huazhong University of Science and Technology
Collaborators